Week in Review: China Unveils New $3.2 Billion Drug Development Program

China announced a new $3.2 billion program to fund innovative drug development, targeting ten major diseases; the CFDA has set up a special program that will speed approvals for novel medical devices; it also began a five-month intensified campaign to root out unsafe medical products in China; Sagent Pharma will invest $30 million to build a second production line at its China production plant; Qiagen will launch its diagnostic blood test for TB in China; Simulations Plus of California signed up a China distributor for its drug development simulation software; and Hua Medicine of Shanghai will start a Phase Ib trial in type 2 diabetics of its novel GKA drug, which produced positive results in an earlier test. More details…. Stock Symbols: (NSDQ: SGNT) (NSDQ: QGEN) (NSDQ: SLP) Share this with colleagues: // //